Dave Lennon was appointed Chief Executive Officer of Satellite Bio in July 2021. Lennon is a 20-year industry veteran driven by the purpose to bring together diverse teams to address the most pressing challenges in medicine to achieve amazing impact for patients and their families.
Prior to Satellite Bio, Lennon spent more than 15 years with Novartis working across multiple therapeutics and geographies. He was most recently President, Novartis Gene Therapies, where he led the approval and launch of Zolgensma, the first systemic gene therapy for spinal muscular atrophy that was approved in more than 40 countries. He also led the expansion of Novartis’s gene therapy research and manufacturing footprint to oversee 5 different sites and more than 2,000 associates. By the time of his departure, Novartis’s gene therapy pipeline had expanded to include 15+ new gene therapy programs, and Zolgensma had achieved blockbuster sales.
Prior to Novartis Gene Therapies, Lennon served in positions of increasing responsibility across Oncology, Neuroscience, Transplant, and Rare Disease therapeutic areas in the U.S., Europe, Japan, and China. Key positions included General Manager Oncology Japan, Solid Tumor Franchise Head USA, and Chief Marketing Officer China. He started his career at Novartis as Global Head, New Products and Portfolio Strategy.
Prior to Novartis, Lennon was an Associate Principal with the New York office of McKinsey & Company, delivering client projects in R&D productivity and consulting in BD&L and M&A transactions.
Lennon earned a PhD in Molecular Medicine from Weill Cornell Medical College of Cornell University and BA in Biophysics from Columbia College of Columbia University.
Interview with Dave (published August 2022) https://mendelspod.com/podcasts/satellite-bio-out-new-tissue-based-appro...